Company intelligence / Profile preview
Rgenta Therapeutics
Woburn, Massachusetts, United Statesrgentatx.com ↗
- Ownership
- Private
- Development stage
- Clinical
01
Overview
Rgenta Therapeutics has advanced its lead candidate RGT‑61159 into a Phase 1a/b clinical trial targeting MYB-driven tumors such as adenoid cystic carcinoma and colorectal cancer. Preclinical data show robust anti-tumor activity in AML models and synergy with standard-of-care therapies. The company also presented promising preclinical results on its proprietary gene expression control system "RSwitch" at major scientific meetings in early/mid‑2025.[2][9]
- Therapeutic areas
- OncologyNeurologyHematology
- Modalities
- Small molecules (oral, RNA-targeting)Gene therapy control systems (RSwitch platform)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
GSK – multi-year strategic research alliance to develop novel RNA-targeted small molecule splice modulators across multiple disease areas including oncology [8].Leukemia & Lymphoma Society Therapy Acceleration Program® – equity investment/support for blood cancer drug development [3][5].
Beyond the preview
Go deeper on Rgenta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rgenta Therapeutics.